Phase 2 ALK Gene Mutation Clinical Trials
4 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Alectinib Pharmacokinetic in Patients With NSCLC
ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 2
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+2 more
Hunan Province Tumor Hospital6,000 enrolled1 locationNCT04322890
Recruiting
Phase 2
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Lung AdenocarcinomaImmunotherapyALK Gene Mutation
Hunan Province Tumor Hospital78 enrolled1 locationNCT05266846
Recruiting
Phase 2
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Non-small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano45 enrolled9 locationsNCT06378892